These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 22053819)

  • 1. Nuclear targeting dynamics of gold nanoclusters for enhanced therapy of HER2+ breast cancer.
    Wang Y; Chen J; Irudayaraj J
    ACS Nano; 2011 Dec; 5(12):9718-25. PubMed ID: 22053819
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S; Horváth G; Knuechel-Clarke R; Hofstaedter F; Szöllosi J; Brockhoff G
    Exp Cell Res; 2005 Apr; 304(2):604-19. PubMed ID: 15748904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative investigation of compartmentalized dynamics of ErbB2 targeting gold nanorods in live cells by single molecule spectroscopy.
    Chen J; Irudayaraj J
    ACS Nano; 2009 Dec; 3(12):4071-9. PubMed ID: 19891423
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
    Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
    Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Her2-positive breast cancer: herceptin and beyond.
    Dean-Colomb W; Esteva FJ
    Eur J Cancer; 2008 Dec; 44(18):2806-12. PubMed ID: 19022660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting fatty acid synthase-driven lipid rafts: a novel strategy to overcome trastuzumab resistance in breast cancer cells.
    Menendez JA; Vellon L; Lupu R
    Med Hypotheses; 2005; 64(5):997-1001. PubMed ID: 15780499
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recombinant human insulin-like growth factor binding protein 3 inhibits growth of human epidermal growth factor receptor-2-overexpressing breast tumors and potentiates herceptin activity in vivo.
    Jerome L; Alami N; Belanger S; Page V; Yu Q; Paterson J; Shiry L; Pegram M; Leyland-Jones B
    Cancer Res; 2006 Jul; 66(14):7245-52. PubMed ID: 16849573
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and in vitro characterization of semitelechelic poly[N-(2-hydroxypropyl)methacrylamide]-trastuzumab conjugates targeted to breast cancer.
    Lee JH; Sabnis G; Nan A
    Macromol Biosci; 2012 Jan; 12(1):55-60. PubMed ID: 22052593
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of adoptive immunotherapy with Herceptin for patients with HER2-expressing breast cancer.
    Kubo M; Morisaki T; Kuroki H; Tasaki A; Yamanaka N; Matsumoto K; Nakamura K; Onishi H; Baba E; Katano M
    Anticancer Res; 2003; 23(6a):4443-9. PubMed ID: 14666732
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Block copolymer micelles target Auger electron radiotherapy to the nucleus of HER2-positive breast cancer cells.
    Hoang B; Reilly RM; Allen C
    Biomacromolecules; 2012 Feb; 13(2):455-65. PubMed ID: 22191486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
    Fan YX; Luo RC; Fang YX; Yan X; Lu CW
    Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting trastuzumab-resistant breast cancer cells with a lentivirus engineered to bind antibodies that recognize HER-2.
    Zhang KX; Kim C; Chow E; Chen IS; Jia W; Rennie PS
    Breast Cancer Res Treat; 2011 Jan; 125(1):89-97. PubMed ID: 20232140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retargeting of adenoviral gene delivery via Herceptin-PEG-adenovirus conjugates to breast cancer cells.
    Jung Y; Park HJ; Kim PH; Lee J; Hyung W; Yang J; Ko H; Sohn JH; Kim JH; Huh YM; Yun CO; Haam S
    J Control Release; 2007 Nov; 123(2):164-71. PubMed ID: 17854941
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.
    Paliwal SR; Paliwal R; Pal HC; Saxena AK; Sharma PR; Gupta PN; Agrawal GP; Vyas SP
    Mol Pharm; 2012 Jan; 9(1):176-86. PubMed ID: 22091702
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Progression and treatment of HER2-positive breast cancer.
    Davoli A; Hocevar BA; Brown TL
    Cancer Chemother Pharmacol; 2010 Mar; 65(4):611-23. PubMed ID: 20087739
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Herceptin-based therapy for breast cancer].
    Tokuda Y; Saito Y; Suzuki Y
    Nihon Rinsho; 2006 Mar; 64(3):540-5. PubMed ID: 16529047
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Predictive value of Her2/neu expression/amplification for the targeted treatment of breast cancer].
    Lehr HA; Schaefer SC; Delaloye JF
    Rev Med Suisse; 2009 Jul; 5(211):1525-9. PubMed ID: 19694364
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
    Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
    Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth effect of neutrophil elastase on breast cancer: favorable action of sivelestat and application to anti-HER2 therapy.
    Nawa M; Osada S; Morimitsu K; Nonaka K; Futamura M; Kawaguchi Y; Yoshida K
    Anticancer Res; 2012 Jan; 32(1):13-9. PubMed ID: 22213283
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
    Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
    Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.